Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy

Molecular Oncology

Volumn 2, Issue 1, 2008, Pages 102-111

  Vargas Roig, Laura M ^a   Cuello Carrión, F Darío ^a   Fernández Escobar, Nicolás ^a   Daguerre, Pedro ^b   Leuzzi, Marcela ^b   Ibarra, Jorge ^b   Gago, Francisco E ^c   Nadin, Silvina B ^a   Ciocca, Daniel R ^a  

^a INSTITUTO ARGENTINO DE NIVOLOGÍA   (Argentina)

^b Hospital Luis Lagomaggiore   (Argentina)

^c UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

Author keywords

Apoptosis; Bcl 2; Breast cancer; Doxorubicin; Neoadjuvant chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL NUCLEUS; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFECT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 43649100347     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2008.01.004     Document Type: Article

References (38)

1. S.S. Apte M.-G. Mattei B.R. Olsen Mapping of the human Bax gene to chromosome 19q13.3–q13.4 and isolation of a novel alternatively spliced transcript Bad Genomics 26 1995 592 594
2. A. Bonetti M. Zaninelli R. Leone G.L. Cetto G. Pelosi S. Biolo A. Menghi E. Manfrin F. Bonetti Q. Piubello Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer Clin. Cancer Res. 4 1998 2331 2336
3. A. Bottini A. Berruti A. Bersiga M.P. Brizzi A. Brunelli G. Gorzegno B. DiMarco S. Aguggini G. Bolsi F. Cirillo p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients Clin. Cancer Res. 6 2000 2751 2758
4. E.H.-Y. Cheng D.G. Kirsch R.J. Clem R. Ravi M.B. Kastan A. Bedi K. Ueno J.M. Hardwick Conversion of Bcl-2 to a Bax-like death effector by caspases Science 278 1997 1966 1968
5. D.R. Ciocca R. Elledge Molecular markers for predicting the response to tamoxifen in breast cancer patients Endocrine 13 2000 1 10
6. F.D. Cuello-Carrión D.R. Ciocca Improved detection of apoptotic cells using a modified in situ TUNEL technique J. Histochem. Cytochem. 47 1999 1 3
7. M.G. Daidone A. Luisi S. Veneroni E. Benini R. Silvestrini Clinical studies of Bcl-2 and treatment benefit in breast cancer patients Endocr. Relat. Cancer 6 1999 61 68
8. M.G. Daidone S. Veneroni E. Benini G. Tomasic D. Coradini M. Mastore C. Brambilla L. Ferrari R. Silvestrini Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer Int. J. Cancer (Pred. Oncol.) 84 1999 580 586
9. X. Deng F. Gao F. May Jr. Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS Blood 102 2003 3179 3185
10. C. Doglioni A.P. Deis Tos L. Laurino C. Chiarelli M. Barbareschi G. Viale The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to estrogen receptor status Virchows Arch. 424 1994 47 51
11. R.M. Elledge D.C. Allred The p53 tumor suppressor gene in breast cancer Breast Cancer Res. Treat. 32 1994 39 47
12. R.M. Elledge S. Green L. Howes G. Clark M. Berardo D.C. Allred R. Pugh D.R. Ciocca P. Ravdin J. O'Sullivan Bcl-2, p53, and response to tamoxifen in ER-positive metastatic breast cancer: a Southwest Oncology Group study J. Clin. Oncol. 15 1997 1916 1922
13. P.A. Ellis I.E. Smith S. Detre S.A. Burton J. Salter R. A'Hern G. Walsh S.R.D. Johnston M. Dowsett Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy Breast Cancer Res. Treat. 48 1998 107 116
14. P. Ellis I. Smith S. Ashley G. Walsh S. Ebbs M. Baum N. Sacs J. McKinna Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer J. Clin. Oncol. 16 1998 107 114
15. M.A. Fanelli F.D. Cuello-Carrión J. Dekker J. Schoemaker D.R. Ciocca Serological detection of heat shock protein hsp27 in normal and breast cancer patients. Cancer Epidemiol Biomarkers Prev. 7 1998 791 795
16. G. Gasparini M. Barbareschi C. Doglioni P. Dalla Palma F.A. Mauri P. Boracchi P. Bevilacqua O. Caffo L. Morelli P. Veredrio Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer Clin. Cancer Res. 1 1995 189 198
17. R. Hoetelmans H.J. van Slooten R. Keijzer S. Erkeland C.J. van de Velde J.H. Dierendonck Bcl-2 and Bax proteins are present in interphase nuclei of mammalian cells Cell Death Differ. 7 2000 384 392
18. D.C. Huang L.A. O'Reilly A. Strasser S. Cory The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry EMBO J. 16 1997 4628 4638
19. D. Kandioler-Eckersberger C. Ludwig M. Rudas S. Kappel E. Janschek C. Wenzel H. Schlagbauer-Wadl M. Mittlböck M. Gnant G. Steger R. Jakesz TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients Clin. Cancer Res. 6 2000 50 56
20. J.F.R. Kerr C.M. Winterford B.V. Harmon Apoptosis. Its significance in cancer and cancer therapy Cancer 73 1994 2013 2026
21. S. Krajewski C. Blomqvist K. Franssila M. Krajewska V.-M. Wasenius E. Niskanen J.C. Reed Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinomas Cancer Res. 55 1995 4471 4478
22. S. Krajewski A.D. Thor S.M. Edgerton D.H. Moore II M. Krajewska J.C. Reed Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers Clin. Cancer Res. 3 1997 199 208
23. K.-H. Lee S.-A. Im D.-Y. Oh S.-H. Lee E.K. Chie W. Han D.-W. Kim T.-Y. Kim I.A. Park D.-Y. Noh Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by placlitaxel as adjuvant chemotherapy BMC Cancer 7 2007 63
24. A. Makris T.J. Powles M. Dowsett C.K. Osborne P.A. Trott I.N. Fernando S.E. Ashley M.G. Ormerod J.C. Titley R.K. Gregory D.C. Allred Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas Clin. Cancer Res. 3 1997 593 600
25. T. Miyashita S. Krajewski M. Krajewska H.G. Wang H.K. Lin B. Hoffman D. Lieberman J.C. Reed Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo Oncogene 9 1994 1799 1805
26. A. Neri D. Marrelli F. Roviello G. DeMarco F. Mariani A. DeStefano T. Megha S. Caruso G. Corso T. Cioppa E. Pinto Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer Breast Cancer Res. Treat. 99 2006 77 83
27. M. Nishita S. Inoue M. Tsuda C. Tateda T. Miyashita Nuclear translocation and increased expression of Bax and disturbance in cell cycle progression without prominent apoptosis induced by hyperthermia Exper. Cell Res. 244 1998 357 366
28. K.N. Ogston I.D. Miller A.C. Schofield A. Spyrantis E. Pavlidou T.K. Sarkar A.W. Hutcheon S. Payne S.D. Heys Can patients’ likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment? Breast Cancer Res. Treat. 86 2004 181 189
29. T. Ohmori E.R. Podack K. Nishio Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2 Biochem. Biophys. Res. Commun. 192 1993 30 36
30. M. Parton S. Krajewski I. Smith M. Krajewska C. Archer M. Naito R. Ahern J. Reed M. Dowsett Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy Clin. Cancer Res. 8 2002 2100 2108
31. L. Pusztai S. Krishnamurti J. Perez Cardona N. Sneige F.J. Esteva M. Volchenok P. Breitenfelder S.W. Kau S. Takayama S. Krajewski Expression of BAG-1 and BCL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer Cancer Invest. 22 2004 248 256
32. N. Shinoura Y. Yoshida M. Nishimura Y. Muramatsu A. Asai T. Kirino H. Hamada Expression level of Bcl-2 determines anti- or pro-apoptotic function Cancer Res. 59 1999 4119 4128
33. R. Silvestrini S. Veneroni M.G. Daidone E. Benini P. Boracchi M. Mezzetti G. Di Fonzo F. Rilke U. Veneronesi The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients J. Natl. Cancer Inst. 86 1994 499 504
34. J. Sjöström C. Blomqvist K. von Boguslawski N.O. Bengtsson I. Mjaaland P. Malmström B. Ostenstadt E. Wist V. Valvere S. Takayama The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer Clin. Cancer Res. 8 2002 811 816
35. Y. Tsujimoto C.M. Croce Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma Proc. Natl. Acad. Sci. U.S.A. 83 1986 5214 5218
36. L.M. Vargas-Roig F.E. Gago O. Tello J.C. Aznar D.R. Ciocca Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy Int. J. Cancer (Pred. Oncol.) 79 1998 468 475
37. L.M. Vargas-Roig F.E. Gago O. Tello M.T. Martin de Civetta D.R. Ciocca c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy Int. J. Cancer (Pred. Oncol.) 84 1999 129 134
38. Z.H. Wang M.X. Ding S.B. Chew-Cheng J.P. Yun E.C. Chew Bcl-2 and Bax proteins are nuclear matrix associated proteins Anticancer Res. 19 1999 5445 5450